黄芪甲苷通过抑制p38 MAPK信号通路改善SD大鼠的肺动脉高压
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金(81973553).


Astragaloside Ⅳ improves pulmonary arterial hypertension by inhibiting p38 MAPK signaling pathway in SD rats
Author:
Affiliation:

Fund Project:

Supported by National Natural Science Foundation of China (81973553).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 研究黄芪甲苷(AS-Ⅳ)对野百合碱(MCT)/野百合碱吡咯(MCTP)诱导SD大鼠/人肺动脉内皮细胞(HPAEC)肺动脉高压(PAH)模型的保护作用和机制。方法 体内实验中,取60只雄性SD大鼠随机分为对照组、PAH模型组、AS-Ⅳ低剂量(20 mg/kg)组、AS-Ⅳ中剂量(40 mg/kg)组、AS-Ⅳ高剂量(80 mg/kg)组、西地那非(Sil,100 mg/kg)组,每组10只;除对照组外,其余各组均采用MCT(60 mg/kg)单次腹腔注射的方法建立PAH大鼠模型。体外实验中,将HPAEC随机分为对照组、PAH模型组、AS-Ⅳ低剂量(10 μmol/L)组、AS-Ⅳ中剂量(20 μmol/L)组、AS-Ⅳ高剂量(40 μmol/L)组、p38 MAPK信号通路抑制剂(SB203580,5 μmol/L)组;除对照组外,其余各组均采用MCTP(60 μg/mL)诱导24 h建立体外PAH细胞模型。体内实验中,药物干预4周后,采用血流动力学方法检测大鼠的右心室收缩压(RVSP)、平均肺动脉压(mPAP),采用称重法检测右心室肥厚指数,采用H-E染色观察肺小动脉管壁厚度占血管外径的百分比(WT%)和管壁面积占血管总面积的百分比(WA%),采用免疫组织化学(IHC)法观察肺组织中caspase 3蛋白表达情况,采用TUNEL法检测肺组织细胞凋亡情况。体外实验中,采用JC-1染色测定细胞中线粒体膜电位的变化情况,采用免疫荧光法检测caspase 3蛋白表达。体内、体外实验中,采用蛋白质印迹法检测肺组织、HPAEC中caspase 3、Bcl-2、Bax、p38 MAPK、磷酸化p38 MAPK蛋白的表达。结果 体内实验中,Sil组与AS-Ⅳ各剂量组RVSP、mPAP、右心室肥厚指数均降低(均P<0.01);AS-Ⅳ各剂量组WA%、WT%均降低(均P<0.01),肺组织中caspase 3蛋白表达降低(均P<0.01),肺组织细胞凋亡降低(均P<0.01)。体外实验中,各剂量AS-Ⅳ和SB203580干预后,HPAEC线粒体膜电位均增高(均P<0.01),caspase 3表达均降低(均P<0.01)。体内、体外实验中,各剂量AS-Ⅳ和SB203580均降低Bax、磷酸化p38 MAPK蛋白表达,增加Bcl-2蛋白表达(均P<0.01)。结论 AS-Ⅳ通过抑制p38 MAPK信号通路减少细胞凋亡,改善SD大鼠PAH。

    Abstract:

    Objective To investigate the protective effect and mechanism of astragaloside Ⅳ (AS-Ⅳ) on the pulmonary arterial hypertension (PAH) model induced by monocrotaline (MCT)/monocrotaline pyrrole (MCTP) in SD rats/human pulmonary artery endothelial cell (HPAEC). Methods In vivo experiment, 60 male SD rats were randomly assigned to control group, PAH model group, AS-Ⅳ low-dose (20 mg/kg) group, AS-Ⅳ medium-dose (40 mg/kg) group, AS-Ⅳ high-dose (80 mg/kg) group, or sildenafil (Sil, 100 mg/kg) group, with 10 rats in each group; except for the control group, PAH rat models were established by single intraperitoneal injection of MCT (60 mg/kg) in other groups. In vitro experiment, HPAECs were randomly assigned to control group, PAH model group, AS-Ⅳ low-dose (10 μmol/L) group, AS-Ⅳ medium-dose (20 μmol/L) group, MCTP+AS-Ⅳ high-dose (40 μmol/L) group, or p38 mitogen-activated protein kinase (MAPK) signaling pathway inhibitor (SB203580, 5 μmol/L) group; except for the control group, in vitro PAH cell models were established by MCTP (60 μg/mL) induction for 24 h in other groups. In vivo experiments, after 4 weeks of drug intervention, the right ventricular systolic pressure (RVSP) and mean pulmonary artery pressure (mPAP) of rats were measured by hemodynamic methods, the right ventricle hypertrophy index was measured by weighing methods, the percentage of pulmonary arteriole wall thickness to outer diameter (WT%) and percentage of the wall area to total vascular area (WA%) were observed by hematoxylin-eosin staining, the expression of cysteine aspartic acid specific protease 3 (caspase 3) protein in lung tissue was observed by immunohistochemistry (IHC), and the apoptosis of lung tissue cells was detected by TUNEL assay. In vitro experiments, JC-1 staining was used to detect the mitochondrial membrane potential in cells, and immunofluorescence was used to detect caspase 3 protein expression. In vitro and in vivo experiments, Western blotting was used to detect the expression of caspase 3, B-cell lymphoma gene 2 (Bcl-2), Bcl-2 associated X protein (Bax), p38 MAPK, and phosphorylated p38 MAPK proteins in lung tissue and HPAECs. Results In vivo experiments, the RVSP, mPAP, and right ventricle hypertrophy index were decreased in the Sil group and each dose group of AS-Ⅳ (all P<0.01); the WA% and WT% of each dose group of AS-Ⅳ were decreased (all P<0.01), the expression of caspase 3 protein in lung tissue was decreased (all P<0.01), and the apoptosis of lung tissue cells was decreased (all P<0.01). In vitro experiments showed that after intervention with each dose of AS-Ⅳ and SB203580, the mitochondrial membrane potential of HPAEC was increased (all P<0.01) and the expression of caspase 3 was decreased (all P<0.01). In vivo and in vitro experiments, each dose of AS-Ⅳ and SB203580 reduced the expression of Bax and phosphorylated p38 MAPK proteins, and increased the expression of Bcl-2 protein (all P<0.01). Conclusion AS-Ⅳ reduces apoptosis by inhibiting p38 MAPK signaling pathway, improving PAH in SD rats.

    参考文献
    相似文献
    引证文献
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-11-12
  • 最后修改日期:2024-05-07
  • 录用日期:
  • 在线发布日期: 2025-08-19
  • 出版日期: 2025-08-20
文章二维码
重要通知
友情提醒: 近日发现论文正式见刊或网络首发后,有人冒充我刊编辑部名义给作者发邮件,要求添加微信,此系诈骗行为!可致电编辑部核实:021-81870792。
            《海军军医大学学报》编辑部
关闭